Clinical TrialsThe TrustTSC trial achieved a significant milestone with the completion of enrollment, setting the stage for upcoming results that could expand the use of Ztalmy.
Financial PerformanceMarinus has implemented cost reduction plans and ended with a strong cash position, expected to support operations well into the next year, reflecting financial stability.
Patent And ProtectionThe USPTO granted a new patent for the treatment of TSC with ganaxolone, providing market exclusivity and protection through 2040, enhancing long-term prospects.